Please login to the form below

Not currently logged in
Email:
Password:

Pfizer generic on hold until 2019

A US district court has ruled against Teva Pharmaceuticals marketing a generic version of Viagra until its Pfizer patent expires in October 2019
A US district court has ruled against Teva Pharmaceuticals marketing a generic version of Viagra until its Pfizer patent expires in October 2019.

Israel-based Teva had claimed Pfizer's patent on Viagra (sildenafil) wasn't valid and couldn't be enforced. It also claimed that Pfizer intentionally withheld documents from the US Patent and Trademark Office.

But US Judge Rebecca Smith, Virginia said that Teva had presented no clear and convincing evidence to support this, in a 110-page opinion.

The decision was made at the end of a two-week non-jury trial. It protects Pfizer's $1bn a year in US Viagra sales.

Pfizer has noted that the decision is subject to appeal. Litigation on the same patent against other companies remains pending.

16th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 women leaders in UK healthcare (part 3)
Part 3 of our list of thirty women leaders...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics